title: Catalytic metalloporphyrin protects against paraquat neurotoxicity in vivo.
abstract: OBJECTIVE
  To examine the neuroprotective effects of a novel manganese porphyrin, manganese (III) meso-tetrakis (N,N'-diethylimidazolium-2-yl) porphyrin (MnTDM), in the mouse model of Parkinson's disease (PD) induced by paraquat (PQ).
  
  
  METHODS
  Male C57BL/6 mice were subcutaneously injected with either saline or PQ at 2-day intervals for a total of 10 doses, MnTDM was subcutaneously injected with the PQ 2 h before treatment. Performance on the pole and swim test were measured 7 days after the last injection and animals were sacrificed one day later. Levels of dopamine (DA) and its metabolites in the striatum were measured by high-performance liquid chromatography with an electrochemical detector (HPLC-ECD). Thiobarbituric acid (TBA) method was used to assay the lipid peroxidation product, malondialdehyde (MDA), and the number of tyrosine hydroxylase (TH) positive neurons was estimated using immunohistochemistry.
  
  
  RESULTS
  Pretreatment with MnTDM significantly attenuated PQ-impaired behavioral performance, depleted dopamine content in striata, increased MDA, and dopaminergic neuron loss in the substantia nigra.
  
  
  CONCLUSIONS
  Oxidative stress plays an important role in PQ-induced neurotoxicity which can be potentially prevented by manganese porphyrin. These findings also propose a possible therapeutical strategy for neurodegenerative disorders associated with oxidative stress such as PD.
authors: School of Life Science and Technology, Tongji University, Shanghai 200092, China.
authors: Ping
authors: P
authors: Chen
authors: Zhen
authors: Z
authors: Chen
authors: Ang
authors: A
authors: Li
authors: Xiao-Chu
authors: XC
authors: Lou
authors: Xiao-Kang
authors: XK
authors: Wu
authors: Chun-Jun
authors: CJ
authors: Zhao
authors: Shi-Long
authors: SL
authors: Wang
authors: Li-Ping
authors: LP
authors: Liang
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D001522:Behavior, Animal / Q000187:drug effects; D002384:Catalysis; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D008665:Metalloporphyrins / Q000627:therapeutic use*; D051379:Mice; D008810:Mice, Inbred C57BL; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D010269:Paraquat; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D013378:Substantia Nigra / Q000187:drug effects / Q000201:enzymology; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
chemical_list: C472668:AEOL 10150; D000975:Antioxidants; D000978:Antiparkinson Agents; D008665:Metalloporphyrins; D018696:Neuroprotective Agents; D008315:Malondialdehyde; D014446:Tyrosine 3-Monooxygenase; D010269:Paraquat; D004298:Dopamine